Study Of Harmony In The Indoor/Outdoor Context Of Architecture Of The 21st Century Catholic Church In Latvia

<p class="04SantraukaPradzia"><span lang="LT">Wide-ranging use of glass systems in modern sacral architecture extends the traditional dialogue between indoor and outdoor space and makes architects look for new forms or harmony between the two, at the same time keeping focus on the most important thing – sense of God’s presence and idea of spiritual transcendence. Compositional application of coloristics, light and shadow under the impact of insolation and visual accents created by the play of light and shadow should underline altarpiece in church space creating the necessary balance and arranging priorities in the right order. Aesthetic harmony has a subordinated significance. A picturesque landscape seen through a glass system has only a subordinate importance. Harmony of indoor/outdoor space in sacral architecture is achieved only in those cases when expressing a hierarchy or priority values such as an altarpiece accentuated with the help of light, interior design opening to the sky, picturesque view of nature. In order to reach the maximum result a synthesis of mentioned methods is recommended.</span></p

TEMPERATURE EFFECTS ON THE ASH COLOUR OF FOREST LITTER / TEMPERATŪROS ĮTAKA MIŠKO PAKLOTĖS PELENŲ SPALVAI

Research was carried out to identify the influence of temperature (150, 250, 350, 450, 550ºC) on the ash colour of Acer platanoides L. leaf litter and Pinus sylvestris L. needle litter samples collected from deciduous coniferous mixed forest in Lithuania (54º43‘ N 25º19‘ E) in April 2010. To achieve the objective, a laboratory experiment was conducted to determine ash samples using the Munsell Colour Chart. The analysis of colours has demonstrated that considering all litter samples, an increase in the temperature of litter heating was found to increase ash colour values (r = 0.92; p = 0.01). All the samples (n = 50) of both litter species were divided into categories 2.5Y (5 samples), 7.5YR (10 samples) and 10YR (35 samples). The total black Munsell colour was observed at a temperature of 350ºC for both litter species. Needle ash started turning bright at a temperature of 550ºC while the complete consumption of leaf litter was visible at a temperature of 450ºC. We conclude that the Munsell Colour Chart used for predicting the colour of ash is an informative feature to have the primary classification of ash. It is imperative to analyse the colour of the litter ash of the selected tree species in order to quickly and easily assess and predict their possible impact on the surrounding environment. Santrauka Tyrimas atliktas siekiant nustatyti temperatūros įtaką (150, 250, 350, 450, 550 ºC) paprastosios pušies spyglių ir paprastojo klevo lapų, surinktų iš lapuočių ir spygliuočių mišraus miško Lietuvoje (54° 43 „N 25° 19 ‚E) 2010-ųjų balandį, pelenų spalvai. Laboratorijoje Munsell spalvų sistema buvo naudojama, norint nustatyti pelenų spalvos reikšmes. Tyrimas parodė, kad didinant degimo temperatūrą visų pelenų spalvų vertės atitinkamai didėjo (r = 0,92, p = 0,01). Pagal spalvų skalę visus mėginius (50) galima suskirstyti į kategorijas: 2.5Y (5 mėginiai), 7.5YR (10 mėginių) ir 10YR (35 mėginiai). Juoda spalva buvo stebima abiejų rūšių pelenuose, kurie buvo deginami 350 ºC temperatūroje. Spyglių pelenai tapo šviesūs esant 550 ºC temperatūrai, o šviesėjantys lapų pelenai pastebėti 450 ºC temperatūroje. Galime teigti, kad Munsell spalvų sistemos naudojimas pelenų spalvai nustatyti yra informatyvus pirminės pelenų klasifikacijos rodiklis. Raktiniai žodžiai: paprastoji pušis; paprastasis klevas; temperatūra; spalva; paklot

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke